Drug spending projected to grow at 6% clip through 2024, spurred in part by pricey new medications; FDA approves new obesity device; Sanofi diabetes combo drug is better at reducing blood glucose than Lantus.

View on a quarter-by-quarter basis the competitive market for four new hepatitis-C treatments and track how Gilead Sciences' Harvoni became the market leader within months of receiving approval from the FDA.